Lovelace Biomedical Research Institute, Albuquerque, NM 87108, USA.
GSK, Collegeville, PA 19426, USA.
Int J Mol Sci. 2024 Apr 2;25(7):3949. doi: 10.3390/ijms25073949.
As a regulator of alveolo-capillary barrier integrity, Transient Receptor Potential Vanilloid 4 (TRPV4) antagonism represents a promising strategy for reducing pulmonary edema secondary to chemical inhalation. In an experimental model of acute lung injury induced by exposure of anesthetized swine to chlorine gas by mechanical ventilation, the dose-dependent effects of TRPV4 inhibitor GSK2798745 were evaluated. Pulmonary function and oxygenation were measured hourly; airway responsiveness, wet-to-dry lung weight ratios, airway inflammation, and histopathology were assessed 24 h post-exposure. Exposure to 240 parts per million (ppm) chlorine gas for ≥50 min resulted in acute lung injury characterized by sustained changes in the ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration (PaO/FiO), oxygenation index, peak inspiratory pressure, dynamic lung compliance, and respiratory system resistance over 24 h. Chlorine exposure also heightened airway response to methacholine and increased wet-to-dry lung weight ratios at 24 h. Following 55-min chlorine gas exposure, GSK2798745 marginally improved PaO/FiO, but did not impact lung function, airway responsiveness, wet-to-dry lung weight ratios, airway inflammation, or histopathology. In summary, in this swine model of chlorine gas-induced acute lung injury, GSK2798745 did not demonstrate a clinically relevant improvement of key disease endpoints.
作为肺泡毛细血管屏障完整性的调节剂,瞬时受体电位香草酸 4(TRPV4)拮抗剂代表了一种有前途的策略,可以减少化学吸入引起的肺水肿。在通过机械通气使麻醉猪暴露于氯气引起的急性肺损伤实验模型中,评估了 TRPV4 抑制剂 GSK2798745 的剂量依赖性作用。每小时测量肺功能和氧合;在暴露后 24 小时评估气道反应性、湿重与干重比、气道炎症和组织病理学。暴露于 240 ppm 氯气≥50 分钟会导致急性肺损伤,其特征为动脉血氧分压与吸气氧浓度分数之比(PaO/FiO)、氧合指数、吸气峰压、动态肺顺应性和呼吸系统阻力在 24 小时内持续变化。氯气暴露还增加了气道对乙酰甲胆碱的反应性,并在 24 小时增加了湿重与干重比。在 55 分钟的氯气暴露后,GSK2798745 略微改善了 PaO/FiO,但对肺功能、气道反应性、湿重与干重比、气道炎症或组织病理学没有影响。总之,在这种氯气诱导的急性肺损伤猪模型中,GSK2798745 并未显示出对关键疾病终点的临床相关改善。